Literature DB >> 21626549

Milestones in PD genetics.

Thomas Gasser1, John Hardy, Yoshikuni Mizuno.   

Abstract

Over the last 25 years, genetic findings have profoundly changed our views on the etiology of Parkinson's disease. Linkage studies and positional cloning strategies have identified mutations in a number of genes that cause several monogenic autosomal-dominant or autosomal-recessive forms of the disorder. Although most of these Mendelian forms of Parkinson's disease are rare, whole-genome association studies have more recently provided convincing evidence that low-penetrance variants in at least some of these, but also in several other genes, play a direct role in the etiology of the common sporadic disease as well. In addition, rare variants with intermediate-effect strengths in genes such as Gaucher's disease-associated glucocerebrosidase A have been discovered as important risk factors. "Next-generation" sequencing technologies are expected by some to identify many more of these variants. Thus, an increasingly complex network of genes contributing in different ways to disease risk and progression is emerging. These findings may provide the "genetic entry points" to identify molecular targets and readouts necessary to design rational disease-modifying treatments.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626549     DOI: 10.1002/mds.23637

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

Review 1.  A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.

Authors:  Akira Nakashima; Akira Ota; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2012-05-27       Impact factor: 3.575

Review 2.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 3.  Therapy for Parkinson's disease: what is in the pipeline?

Authors:  Fabrizio Stocchi
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 5.  Challenges in essential tremor genetics.

Authors:  L N Clark; E D Louis
Journal:  Rev Neurol (Paris)       Date:  2015-05-21       Impact factor: 2.607

Review 6.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

Review 7.  Evolution of neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Biol       Date:  2012-09-11       Impact factor: 10.834

8.  Genetic risk factors in Parkinson's disease: single gene effects and interactions of genotypes.

Authors:  Anna Göbel; Eric A Macklin; Susen Winkler; Rebecca A Betensky; Christine Klein; Katja Lohmann; David K Simon
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

Review 9.  Essential tremor.

Authors:  Lorraine N Clark; Elan D Louis
Journal:  Handb Clin Neurol       Date:  2018

10.  PLK2 modulates α-synuclein aggregation in yeast and mammalian cells.

Authors:  Elisa Basso; Pedro Antas; Zrinka Marijanovic; Susana Gonçalves; Sandra Tenreiro; Tiago Fleming Outeiro
Journal:  Mol Neurobiol       Date:  2013-05-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.